{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:24:46Z","timestamp":1794608686734,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-110959"],"award-info":[{"award-number":["MOP-110959"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Arthritis Cohort (CATCH)"},{"name":"Centre de recherche clinique du Centre hospitalier universitaire de Sherbrooke"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-0935-z","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T08:01:57Z","timestamp":1454313717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Serum levels of 14-3-3\u03b7 protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis"],"prefix":"10.1186","volume":"18","author":[{"given":"Nathalie","family":"Carrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur J.","family":"de Brum-Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Masetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri A.","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Boire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"935_CR1","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum."},{"key":"935_CR2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39:1559\u201382.","journal-title":"J Rheumatol."},{"key":"935_CR3","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3899\/jrheum.120100","volume":"39","author":"R Tavares","year":"2012","unstructured":"Tavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, et al. Time to disease modifying anti-rheumatic drug treatment in rheumatoid arthritis and its predictors: A national, multi-center, retrospective cohort. J Rheumatol. 2012;39:2088\u201397.","journal-title":"J Rheumatol."},{"key":"935_CR4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","volume":"50","author":"DP Rooy de","year":"2011","unstructured":"de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes\u2014What can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50:93\u2013100.","journal-title":"Rheumatology (Oxford)"},{"key":"935_CR5","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar4547","volume":"16","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, Van Der Heijde D, Allaart CF, Landew\u00e9 R, Boire G, Tak PP, et al. 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014;16:R99.","journal-title":"Arthritis Res Ther."},{"key":"935_CR6","first-page":"1650","volume":"34","author":"RT Kilani","year":"2007","unstructured":"Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007;34:1650\u20137.","journal-title":"J Rheumatol."},{"issue":"Suppl 85","key":"935_CR7","first-page":"S35","volume":"32","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, Marotta A. 14-3-3eta: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol. 2014;32 Suppl 85:S35\u20139. Review.","journal-title":"Clin Exp Rheumatol."},{"key":"935_CR8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/art.24353","volume":"60","author":"N Carrier","year":"2009","unstructured":"Carrier N, Cossette P, Daniel C, de Brum-Fernandes AJ, Liang P, M\u00e9nard HA, et al. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies. Arthritis Rheum. 2009;60:698\u2013707.","journal-title":"Arthritis Rheum."},{"key":"935_CR9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/acr.20288","volume":"62","author":"MC Guzian","year":"2010","unstructured":"Guzian MC, Carrier N, Cossette P, de Brum-Fernandes AJ, Liang P, M\u00e9nard HA, et al. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. Arthritis Care Res. 2010;62:1624\u201332.","journal-title":"Arthritis Care Res."},{"key":"935_CR10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/acr.21923","volume":"65","author":"PL Dobkin","year":"2013","unstructured":"Dobkin PL, Liu A, Abrahamowicz M, Carrier N, de Brum-Fernandes AJ, Cossette P, et al. Predictors of pain for patients with early inflammatory polyarthritis. Arthritis Care Res. 2013;65:992\u20139.","journal-title":"Arthritis Care Res."},{"key":"935_CR11","doi-asserted-by":"crossref","unstructured":"Fries JF,\u00a0Hunder GG,\u00a0Bloch DA,\u00a0Michel BA,\u00a0Arend WP,\u00a0Calabrese LH, et al.\u00a0The\u00a0American\u00a0College\u00a0of\u00a0Rheumatology\u00a01990\u00a0criteria\u00a0for the\u00a0classification\u00a0of\u00a0vasculitis.\u00a0Summary. Arthritis Rheum.\u00a01990;33(8):1135-6.","DOI":"10.1002\/art.1780330812"},{"key":"935_CR12","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","volume":"350","author":"JR O\u2019Dell","year":"2004","unstructured":"O\u2019Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591\u2013602.","journal-title":"N Engl J Med."},{"key":"935_CR13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.rdc.2009.10.009","volume":"35","author":"T Pincus","year":"2009","unstructured":"Pincus T, Yazici Y, Bergman MJ. Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical history. Rheum Dis Clin N Am. 2009;35:735\u201343.","journal-title":"Rheum Dis Clin N Am."},{"key":"935_CR14","first-page":"261","volume":"27","author":"D Heijde Van der","year":"2000","unstructured":"Van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000;27:261\u20133.","journal-title":"J Rheumatol."},{"key":"935_CR15","first-page":"2306","volume":"29","author":"K Bruynesteyn","year":"2002","unstructured":"Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol. 2002;29:2306\u201312.","journal-title":"J Rheumatol."},{"key":"935_CR16","doi-asserted-by":"crossref","first-page":"R592","DOI":"10.1186\/ar1719","volume":"7","author":"G Boire","year":"2005","unstructured":"Boire G, Cossette P, de Brum Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, et al. Anti-Sa antibodies and antibodies to cyclic citrullinated peptides (CCP) are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther. 2005;7:R592\u2013603.","journal-title":"Arthritis Res Ther."},{"key":"935_CR17","unstructured":"Anti-Sa ELISA (IgG). In: EUROIMMUN Medizinische Labordiagnostika. 2010. http:\/\/www.euroimmun.ch\/uploads\/media\/EA_151a_D_UK_A02_Anti-SA.pdf . Accessed 17 October 2015."},{"key":"935_CR18","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100\u20138.","journal-title":"Clin Exp Rheumatol."},{"key":"935_CR19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3899\/jrheum.131446","volume":"41","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, Naides SJ, Bykerk VP, Siminovitch KA, van Schaardenburg D, Boers M. Serum 14-3-3\u03b7 is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104\u201313.","journal-title":"J Rheumatol."},{"key":"935_CR20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","volume":"17","author":"S Hirata","year":"2015","unstructured":"Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015;17:280.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-0935-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:56:22Z","timestamp":1498265782000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/18\/1\/37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-0935-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]},"article-number":"37"}}